INS and polycystic ovary syndrome: These differences may influence the impact of metformin in each group [63]: whereas reproductive benefits are observed in both obese and lean PCOS women [64], metabolic advantages, such as lowering of proinsulin and insulin levels, are seen predominantly in the obese and overweight subset [65].